Compare Eli Lilly And Co (LLY) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs State Street Technology Select Sector SPDR ETF — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while State Street Technology Select Sector SPDR ETF trades at $198.92 (market cap $132.55B). The key difference: Eli Lilly And Co is far larger — about 7.8× State Street Technology Select Sector SPDR ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while State Street Technology Select Sector SPDR ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| LLY | XLK | |
|---|---|---|
Market Cap | $1.04T | $132.55B |
Volume | 3,064,878 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $1.28K | $202.00 |
52-Week Low | $799.57 | $127.49 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
XLK trades at $198.68, down 1.35% on the day, with technical indicators showing a bullish overall signal driven by strong moving average support. The ETF maintains neutral oscillators with RSI readings around 60, suggesting balanced momentum. Recent news highlights ongoing investor focus on AI sector dynamics and concentration concerns within XLK's holdings, particularly its heavy chip exposure that may limit diversification benefits despite quarterly rebalancing.
The outlook for XLK remains tied to technology sector performance and AI investment trends, with potential upside from continued enterprise software strength and semiconductor demand. Key risks include interest rate sensitivity, sector concentration, and competitive ETF alternatives offering better risk-adjusted returns. Investors should weigh XLK's cost efficiency against its mega-cap heavy structure when considering technology exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
